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Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia
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Sarah Cristina Bassi
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Acute promyelocytic leukemia is characterized by gene rearrangements that always involve the
retinoic acid receptor alpha on chromosome 15. In the majority of patients t(15;17) is detected,
which generates the promyelocytic leukemia gene/retinoic acid receptor alpha rearrangement. This
rearrangement interacts with several proteins, including the native promyelocytic leukemia gene,
thus causing its delocalization from the nuclear bodies, impairing its function. The immuno-
fluorescence staining technique using the anti-PML antibody may be used to provide a rapid
diagnosis and to immediately start therapy using all-trans retinoic acid. The experience of the
International Consortium on Acute Promyelocytic Leukemia has demonstrated that early mortality
was significantly reduced by adopting the immunofluorescence technique. All-trans retinoic acid
combined with chemotherapy is the standard therapy; this promotes complete remission rates
greater than 90% and cure rates of nearly 80%. However, early mortality is still an important
limitation and hematologists must be aware of the importance of treating newly diagnosed acute
promyelocytic leukemia as a medical emergency.
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Introduction
The clinical features of acute promyelocytic leukemia (APL) were first described in
1949 by Croizat & Favre-Gilly.(1) Only in 1957, Hillestad recognized APL as a specific
subtype of acute myelocytic leukemia (AML), highlighting the peculiar clinical features
and laboratorial aspects of this entity.(2) Furthermore, in 1969, Rand speculated that
leukemic cells were probably responsible for the activation of the fibrinolytic system.(3)
But it was only in 1977 that Rowley described the characteristic translocation of APL(4)
and, finally in 1999 the genes involved in the t(15;17) were cloned and characterized.(5)
The introduction of all-trans retinoic acid (ATRA) in 1988 in the therapy of APL has
revolutionized the management and outcome of this disease and, provided the first
paradigm of molecular targeted treatment.(6) As a result, APL is today the most curable
acute leukemia.
Molecular and cytogenetic bases
The characteristic feature of APL is the break and fusion of the promyelocityc
leukemia (PML) gene located in chromosome 15 and retinoic acid receptor alpha (RARA)
located in chromosome 17, resulting in a t(15;17). This translocation is detected in more
than 90% of APL cases(4) and produces two genes that encode the PML-RARA and
RARA-PML hybrid proteins (the last detected in only 70% of cases).(5,7)
The PML gene is essential to many apoptotic pathways and is implicated in the
control of genomic stability. Its inactivation in animal models caused resistance to
apoptosis induced by several stimuli, increased cell growth and deregulated cell
senescence.(8,9) In the nucleus, the PML protein is detected in nuclear structures as nuclear
bodies (NBs), interacting with other proteins (p53, pRB, Daxx, CBP).(10) In t(15;17), the
breakpoint in the PML gene occurs in three different sites: intron 6 (bcr1-breakpoint
cluster region 1), exon 6 (bcr-2 - breakpoint cluster region 2), and intron 3 (bcr-3 -
breakpoint cluster region 3).(11) Independently of the bcr subtype, most of the functional
domains are conserved in the PML/RARA fusion protein.
The RARA nuclear receptor is distributed according to specific standards in each
tissue and is particularly important for granulopoiesis.(12) Structurally, RARA has six
functional domains five of which are preserved in the protein of the PML/RARA fusion.(5)
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In the presence of physiological concentrations of ATRA,
the RARA protein is capable of linking to the receptor and
migrating from the cytoplasm to the nucleus consequently
dimerizing with a second class of retinoid receptors, the retinoic
X receptor (RXR). This complex recognizes specific sequences
of oligonucleotides present in the promoter regions of many
genes. By self-linking to the nuclear co-repressors (N-Cor)
Sin3a and Sin3b and, subsequently, to histone deacetylases
(HDAC), it deacetylates histones, with consequent
compaction of chromatin and repression of gene transcription.
DNA methyltransferases (DNMT) are also part of the
transcriptional repressing complex and are responsible for
DNA methylation.(13) Hence, the expression of the PML/
RARA oncoprotein is a deregulation of the epigenetic control
in terms of both aberrant histone modification and DNA
methylation in critical gene chromatin domains.
The PML-RARA oncoprotein is able to interact with
the parental proteins through its protein-protein interaction
domains. In the case of PML, the expression of the PML/
RARA oncoprotein leads to the delocalization of normal PML
from its subcellular site, nuclear structures known as NBs.
As a result, PML/RARA negatively acts on the function of
the native PML protein.(10)
There are other chromosomal translocations associated
with APL such as the t(11,17)(q23,q21), that generates the
promyelocytic leukemia zinc finger (PLZF)/RARA hybrid gene
with a frequency estimated at approximately 1%, and the
t(11,17)(q13,q21) and interstitial duplication of 17q21-q23
generating, respectively, the nuclear matrix-mitotic apparatus
(NµMA)/RARA and signal transducer and activator of
transcription (STAT5b)/RARA hybrid genes both with
frequencies of less than 1%.(14) There are other translocations
described such as the t(5,17)(q35,q21) generating the NPM
(Nucleophosmin)/RARA hybrid genes, the t(4;17)(q12;q21)
generating the FIP1L1/RARA hybrid genes and 17(17q24)
generating PRKAR1A/RARA hybrid gene. These variant
translocations lead to the formation of fusion proteins
generally known as X/RARA, with differentiated sensitivity
to retinoid acids. NµMA/RARA, FIP1L1/RARA and NPM1/
RARA are known for being ATRA-sensitive, whereas PLZF/
RARA, PRKAR1A/RARA and STAT5b/RARA have different
degrees of resistance to ATRA.(6,14-16)
Epidemiology
APL predominantly affects adults between 20 and 59
years and there is no gender difference.(17) APL secondary to
therapy is unusual, with a relative frequency close to 5%.(6,18,19)
Around 10-15% of the AML diagnosed in adults are APL.(18,19)
However, in some countries the proportion of APL cases
among LMAs is higher; this includes Brazil (28.2%),(20) Mexico
(20%),(21) Venezuela (27.8%)(22) and Peru (22%).(23) Whether
there is a genetic cause underlying the differences in the
geographic distribution of APL is controversial. A study
involving 12 Brazilian institutions showed an elevated
frequency of the high relapse risk group as defined by the
cooperative groups Programa Español de Tratamientos en
Hematología (PETHEMA) and Gruppo Italiano Malattie
Ematologiche dell'Adulto (GIMEMA) (36.9% versus
22.6%).(20,24,25)
Clinical and laboratorial aspects
Constitutional symptoms resemble those of other
AML, such as fever, fatigue, diminished appetite and
weight loss. Characteristically, there is a tendency to bleed,
disproportionate to thrombocytopenia. Bleeding events are
present in about 60 to 80% of patients and this is the main
reason for the high mortality rates during the early stages of
treatment.(10,26-30)
The coagulopathy depends on three factors: activation
of the coagulation cascade, increased fibrinolysis and
proteolysis.(10) The promyelocytes of APL are able to activate
the coagulation cascade by expressing tissue factor (TF)(31,32)
and increase procoagulant activity in endothelial cells by
expressing interleukin 1β1 and tumor necrosis factor
alpha.(33,34) In addition to these components, an isolated
cysteine proteinase, a cancer procoagulant (CP) is released
from blasts and directly activates factor X, maximizing the
formation of thrombin and consequently fibrin.(35,36) The state
of hyperfibrinolysis is evidenced by decreased fibrinogen,
increased fibrin degradation products (D-dimer, fibrino-
peptide A, prothrombin fragment 1+2 and thrombin-
antithrombin complex), increased tPA (tissue plasminogen
activator) and uPA (activator urokinase plasminogen),(35) and
reduced levels of plasmin inhibitor α2 (α2PI),(35) plasminogen
activator inhibitor-1 (PAI-1)(37) and 2-antiplasmin.(38) The
coagulopathy of APL is usually described as similar to
disseminated intravascular coagulation (DIC). However, both
the average life of platelets and the levels of the natural
anticoagulants, protein C and antithrombin, are normal in
APL in contrast with DIC.(39,40) Furthermore the bleeding
manifestations are disproportionate to the laboratory
abnormalities observed.
Although the concentration of thrombin activated
fibrinolysis inhibitor (TAFI) is normal, its activity is markedly
reduced.(41) This change results in a framework compatible to
an increased production of plasmin. There is also an increased
expression of annexin II on leukemic cells of APL.(37) Other
factors contribute to coagulation such as increased serum levels
of elastase,(42) increased concentrations of von Willebrand
factor and its fragments in circulation(43) and recently,
microparticles containing TF, tPA, PAI-1 and annexin II.(44)
The complete blood counts usually show
pancytopenia. Blasts with promyelocyte morphology are seen
in peripheral blood. Most patients with APL have abnormal
hemostasis tests, such as prolonged prothrombin time,
prolonged activated partial thromboplastin time, prolonged
thrombin time, hypofibrinogenemia, increased levels of fibrin
degradation products and fibrin D-dimer.
Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia
136                                                                                                                                              Rev Bras Hematol Hemoter. 2012;34(2):134-9
Bassi SC, Rego EM
The bone marrow aspirate normally shows an infiltration
(commonly higher than 20% of nucleated cells) that is
intensely positive to Sudan black and myeloperidoxidase
markers. Two morphological subtypes occur: the hyper-
granular and hypogranular (microgranular) patterns, the last
corresponding to 25% of the cases.(16) The classic form is
characterized by the presence of abnormal promyelocytes
with abundant azurophilic granulation, irregular nuclei and
Auer rods (frequently organized in bundles, characterizing
cells known as Faggots).(16) In the hypogranular variant,
usually associated with leukocytosis, a large number of blasts
with reniform or bilobulated nuclei and discrete cytoplasmic
granulation are observed.(16) There may be coexistence of a
low number of typical hypergranular blasts. There is also a
rare hyperbasophilic form associated with relapse.(16)
The immunophenotyping study of APL with t(15,17)
(q22;q12) (hypergranular or "typical" variant) is characterized
by blasts with high auto-fluorescence, expressing early
myeloid markers such as CD117 (with low fluorescence
intensity), CD13 and CD33 are also positive expressing
heterogeneous and homogenous patterns of fluorescence
intensity, respectively. The CD34 hematopoietic progenitor
cell marker is negative or has a low expression, as does
HLA-DR. The granulocytic differentiation markers CD15,
CD11b and CD65 are negative or only weakly expressed and
CD64 expression is common. In cases of microgranular
morphology, which is frequently associated with the bcr3
subtype, blasts frequently co-express the T lineage-affiliated
marker CD2 with myeloid markers CD13 and CD34, at least
on a fraction of cells. For being a fast method, immuno-
phenotyping is useful to investigate for APL, but it is not
an appropriate method to confirm diagnosis.(6,16)
Confirmation of diagnosis must use techniques able to
detect t(15;17) or the PML-RARA hybrid gene. Conventional
cytogenetics, fluorescence in situ hybridization (FISH) and
polymerase chain reaction by reverse transcriptase (RT-PCR)
are the available options.(6)
Karyotyping on G-banded metaphases is usually
performed by conventional methods on direct, 24-hour, and
48-hour cultures. It has the advantage of allowing the diagnosis
of additional cytogenetic alterations, however it takes longer
and is more expensive and it is not always possible to observe
metaphases in the number and quality needed for analysis. In
addition, secondary chromosomal abnormalities do not seem
to have significant prognostic value in APL.(6)
RT-PCR is widely used for diagnosis. Standardized
assays were established by the Biomed-1 Concerted Action
group and allow the identification of the three main break
points of PML (bcr1, bcr2 and bcr3), fundamental for the
research of minimal residual disease. The drawbacks of the
method are the possibility of RNA deterioration,
contamination and artifacts, which may lead to false results
and a prolonged performing time.(6)
Another option available nowadays is immuno-
fluorescence with anti-PML (PGM3). In patients with the PML-
RARA rearrangement, PML is found redistributed and it is
possible to observe, by microscopy, a microparticle pattern.
In the other LMA subtypes, the technique reveals only 8 to
10 large structures, which are NBs. Dimov et al. determined
that the sensitivity and specificity of the anti-PML technique
were 98.9% and 98.7%, respectively.(45) Immunofluorescence
is useful for a faster diagnosis particularly where molecular
methods are unavailable. However, this should not replace
molecular confirmation.(6)
Treatment
The combination of ATRA and anthracycline is
currently considered the standard induction treatment in
newly diagnosed patients(6) leading to a complete remission
(CR) rate of 90 to 95%.(46) Two randomized trials(30,47) show
that ATRA in association with other chemotherapy resulted
in better outcomes mainly because of lower relapse rates.(46)
However, which anthracycline is the best remains
controversial.(6) The PETHEMA(48) and GIMEMA groups(49)
used idarubicin and the International Consortium on Acute
Promyelocytic Leukemia (IC-APL) used daunorubicin with
similar results.(50)
Arsenic trioxide (ATO) is the most effective single drug
against APL. It has been widely used as a single agent in
induction in India and China with CR rates above 70%. A
relatively good long-term remission can be obtained by using
ATO as a single agent in newly diagnosed patients as has
been evidenced with a 2-year disease-free survival rate (DFS)
of 63.7% and a 3-year DFS of 87.2% in a large cohort of
patients from India.(51)
Aggressive transfusion therapy is central in APL
treatment, thus reducing cases of fatal bleeding.(6,18) Platelets
are transfused to maintain the platelet count higher than from
30 x 103/µL to 50 x 103/µL, fresh frozen plasma is indicated to
correct abnormal hemostasis and cryoprecipitate is
administered to maintain the fibrinogen level higher than from
100 to 150 mg/dL. These tests should be performed at least
once a day (more frequently if required).(18) Placement of a
central venous catheter, lumbar puncture and other invasive
procedures should be avoided until the coagulation
abnormalities are resolved.(6)
Treatment with ATRA should be started immediately
based only on clinical suspicion, even before the genetic
confirmation. This measure itself leads to improvement of
the coagulopathy and reduced risk of severe bleeding.(6)
ATRA acts not only on cell cycle, but also leads to
normalization of plasminogen, α2-plasminogen inhibitor,
fibrinogen, D-dimers, the thrombin-antithrombin complex
(TAT) and fibrinopeptides. It promotes a reduction in TF
expression, resulting in an improvement of coagulation tests
within 4-5 days. Nevertheless, it is paradoxically associated
with thrombotic complications later in the course of the
disease (usually 1-3 weeks after treatment introduction)
because of an increase in tPA expression.(52)
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Regarding the consolidation therapy, the experience of
the PETHEMA and GIMEMA groups suggests that therapy
should be based on the relapse risk group (Table 1) with
higher anthracycline doses in intermediate and high risk
groups. Even so, patients classified as high risk still have
relapse rates above 20%.(46)
baseline (1-year OS: 59% for high, 87% for intermediate, 91%
for low, p-value = 0.0007) and age. The 1-year OS was 85% for
age < 25, 83% for 25-40, and 58% for age ≥ 40 (p-value = 0.008
for age ≥ 40 vs. < 40). In the Cox model, these two prognostic
factors remain significantly associated with the OS [HR =
3.77, p-value = 0.004 for high relapse risk score; HR = 2.4,
p-value = 0.047 for age ≥ 40]. In conclusion, the establishment
of the IC-APL network resulted in a decrease of about 40% in
early mortality and improvements in outcome to levels similar
to those reported in developed countries.(50)
Differentiation syndrome
Both ATRA and ATO, alone or in combination, can
trigger DS. The incidence of DS is approximately one quarter
of all APL patients receiving ATRA as induction therapy.(54)
The combination of ATRA and ATO has an incidence of
16%.(55) DS usually starts between the third and fourteenth
day of treatment with ATRA, but there are some reports after
the first dose.(54) The clinical manifestations are quite varied
and should be suspected in the presence of these signs and
symptoms: shortness of breath with or without edema or
pulmonary infiltrates and often mistaken for fluid overload
with pleural effusions or pneumonia, fever, bone pain, weight
gain, hypotension, edema, heart failure, kidney failure, cavity
stroke and headache (which should be differentiated from
the syndrome of pseudotumor cerebri). Sweet's syndrome
and other findings are observed, usually preceded by an
elevated WBC count.(6) The etiology of this syndrome is not
fully understood. It is believed that there is an inflammatory
process due to an excessive infiltration of different organs
by myeloid cells with differential expression of adhesion
molecules and cytokine production.(54,56) Early identification
of symptoms and treatment are essential because retinoid
syndrome leads to decreased EFS and OS. If the symptoms
or signs are severe, ATRA (or ATO) should be discontinued
and resumed at resolution of all signs and symptoms with
the association of 10 mg dexamethasone twice daily(6) for at
least three days until resolution of symptoms.(10)
Monitoring
Cytogenetics and molecular testing are not needed at
the end of induction because they have no prognostic value.
In contrast, the detection of the PML/RARA fusion gene at
the end of the third course of consolidation should be
considered as resistance and the patient should receive
alternative treatment. After maintenance therapy is completed,
the frequency of monitoring is not clearly established. The
good outcome for patients presenting with low risk disease
is so favorable that frequent monitoring can be questioned.
Patients with intermediate risk disease should be monitored
every three to six months and those with high-risk disease
every three months during and after the completion of
maintenance therapy.(6,18)
The relevance of maintenance therapy is controversial.
Studies by the European APL group showed that the relapsed
risk was increased in patients that did not receive
maintenance.(53) Maintenance was adopted in the PETHEMA
and GIMEMA trials, but no randomized comparisons were
performed in order to establish whether maintenance is
essential. Only a Japanese study compared no maintenance
versus six courses of intensified maintenance chemotherapy
without ATRA. This study showed no benefit from the use
of chemotherapy alone in terms of reducing relapse rates
with a significantly lower chance of survival in the
maintenance arm. Despite the uncertainty of the benefit
provided by maintenance therapy, the fact is that many
patients who are PCR negative at the end of the consolidation
will eventually relapse, especially those with high white blood
cell (WBC) counts at diagnosis.(46)
The IC-APL adopted a treatment protocol based on the
APL 2005 PETHEMA protocol, except that idaurubicin was
replaced by daunorubicin. An interim analysis of 102 patients
enrolled in Brazil, Mexico, Chile and Uruguay showed that
the distribution of the relapse risk score at diagnosis
according to PETHEMA-GIMEMA criteria was 14 low (14%),
54 intermediate (53%) and 34 high risk (33%). The incidence
of low risk APL appeared lower than the values reported in
developed countries.
Of 102 patients, 97 have toxicity and response data
available; 12 (12.3%) experienced at least three symptoms/signs
of differentiation syndrome (DS) and 77 (79%) patients
achieved CR. Twenty-three deaths occurred with the causes
of deaths including nine hemorrhages, eight infections and
two DS. The 7- and 30-day mortality rates were 8% and 19.6%,
respectively, the 1-year overall survival (OS) was 75% (95%
confidence interval - 95% CI: 68%-84%). The median follow-
up time among survivors was 14 months (range: 1.3-35 months).
Of the 77 patients who achieved CR, the 1-year OS from the
date of CR was 95% (95% CI: 89%-100%); only one patient
relapsed. For patients surviving a minimum of 30 days, the
outcome was similar to that reported by the PETHEMA-APL
2005 protocol in European patients. Prognostic factors for OS
were examined using log-rank test as well as multivariate Cox
models. Factors predicting OS were a high relapse risk score at
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Relapse
Hematologic relapse follows the same criteria of
diagnosis. Molecular relapse is considered in the presence
of two consecutive positive RT-PCR results obtained with a
minimum interval of two weeks. Initially salvage therapy
was performed with anthracycline or mitoxantrone
associated with intermediate or high doses of cytarabine,
with or without etoposide, followed by transplantation.
These regimens resulted in high rates of second CR (80% to
90%).(22) Since the availability of ATO, excellent results are
obtained with this drug as a single agent in patients with
relapse and refractory APL. The drug has three main
mechanisms of action: 1) production of reactive oxygen
species that induce the phosphorylation and activation of
the Jun N-terminal kinase (JNK) pathway, triggering
apoptosis; 2) phosphorylation of sumolization of PML/
RARA, leading to its degradation; 3) inhibition of
transcription of hTERT and consequent decrease in
telomerase activity, leading to chromosome fusion and
apoptosis.(10) The most significant adverse reactions are DS,
gastrointestinal discomfort, elevated liver enzymes, neuro-
pathy, hyperglycemia and cardiac arrhythmias (prolongation
of the QT interval - careful monitoring is recommended to
maintain the serum potassium above 4.0 mEq/L and serum
magnesium above 1.8 mg/dL). ATO is administered intra-
venously at a dose of 0.15 mg/kg/d until hematologic
remission or for a maximum of 60 days. There are reported
rates of second CR of 80 to 90% and OS at one to three years
of 50% to 70%. The results of molecular response to therapy
after two cycles of ATO (one induction and one consolidation
course) should then be taken into account for additional
decisions on the continuation of therapy and, in particular,
to identify patients at higher risk of additional relapse (i.e.,
those with persistent PCR positivity) who must be, when
feasible, allocated to allogeneic hematopoietic stem cell
transplantation. Therefore, the available options include
continued treatment with ATO and/or chemotherapy plus
ATRA followed by transplantation. So far there are no
studies that compare autologous and allogeneic bone
marrow transplantation. Four weekly courses of intrathecal
methotrexate or alternating methotrexate and Ara-C should
be given because of possible increases in the incidence in
central nervous system relapse, especially for those patients
with leukocytosis at presentation.(6,46)
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